Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 7/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.34 |
| ▸ | S100A10 | P60903 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429529 | 0.94 | DDR1 (0.38) | DDR1MAOBMAOACTSSCTSK | |
| SCHEMBL5432523 | 0.92 | MAOB (0.37) | DDR1MAOBMAOAALDH1A2ALDH1A3 | |
| SCHEMBL5426687 | 0.91 | CYP1A2 (0.40) | MAOBMAOACNR1ALDH1A2ALDH1A3 | |
| SCHEMBL5429455 | 0.91 | MAOB (0.40) | DDR1MAOBMAOAALDH1A2ALDH1A3 | |
| SCHEMBL5437043 | 0.88 | MAT2A (0.42) | MAOBMAOAALDH1A2ALDH1A3TP53 | |
| SCHEMBL5429829 | 0.88 | MAOB (0.50) | MAOBMAOAALDH1A2ALDH1A3TP53 | |
| SCHEMBL5440484 | 0.85 | DDR1 (0.39) | DDR1MAOBMAOATP53 | |
| SCHEMBL5431686 | 0.83 | MAOB (0.40) | DDR1MAOBMAOAALDH1A2ALDH1A3 | |
| SCHEMBL5434559 | 0.83 | MAOA (0.39) | MAOBMAOACNR1ALDH1A2ALDH1A3 | |
| SCHEMBL5437860 | 0.82 | MAOB (0.52) | MAOBMAOAALDH1A2ALDH1A3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | DDR1 725/4885MAOB 3067/4885MAOA 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.